{"brief_title": "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis", "brief_summary": "To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.", "condition": "End-Stage Kidney Disease", "intervention_type": "Drug", "intervention_name": "Calcijex", "criteria": "Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin D therapy", "gender": "All", "minimum_age": "20 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00062699.xml"}